Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-19-026634
Filing Date
2019-11-05
Accepted
2019-11-05 06:05:54
Documents
1
Period of Report
2019-11-04

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 6076
  Complete submission text file 0000899243-19-026634.txt   7648
Mailing Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540
Business Address 202 CARNEGIE CENTER SUITE 109 PRINCETON NJ 08540 (609) 382-9032
Oyster Point Pharma, Inc. (Issuer) CIK: 0001720725 (see all company filings)

EIN.: 811030955 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 11 LINDA ISLE NEWPORT BEACH CA 92660
Business Address 11 LINDA ISLE NEWPORT BEACH CA 92660 714-299-1864
OYSTER POINT PHARMA I, LLC (Reporting) CIK: 0001769046 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 4 | Act: 34 | File No.: 001-39112 | Film No.: 191191622